BRIEF published on 08/27/2024 at 13:05, 1 year 3 months ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 1 year 3 months ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 1 year 3 months ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 1 year 5 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 1 year 5 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 1 year 5 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 1 year 5 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 1 year 5 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 1 year 5 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 1 year 7 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 12/17/2025 at 09:05, 1 hour 41 minutes ago Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Published on 12/17/2025 at 08:00, 2 hours 46 minutes ago Pulsar Helium Awards Security Based Compensation
Published on 12/16/2025 at 23:20, 11 hours 26 minutes ago Tactical Resources Announces Shareholder Approval of Arrangement With Plum Acquisition Corp. III
Published on 12/16/2025 at 23:20, 11 hours 26 minutes ago GMV Minerals Announces Upsize of Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/16/2025 at 23:07, 11 hours 39 minutes ago Linear Minerals Corp Closes First Tranche of Private Placement Financing
Published on 12/17/2025 at 10:05, 41 minutes ago UTI Investments Partners with FTSE Russell to Transition its Sovereign Bond ETF Benchmark
Published on 12/17/2025 at 09:30, 1 hour 16 minutes ago Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth
Published on 12/16/2025 at 20:10, 14 hours 36 minutes ago donation of shares of Seval, member of the Feuillet family concert
Published on 12/16/2025 at 20:10, 14 hours 36 minutes ago Donation de titres de la société Seval, membre du concert familial Feuillet
Published on 12/16/2025 at 18:53, 15 hours 53 minutes ago Number of shares and voting rights - November 2025 (In French only)
Published on 12/16/2025 at 18:53, 15 hours 53 minutes ago Nombre total d'actions et droits de vote - novembre 2025
